Prothena Corporation plc
PRTANASDAQHealthcare● Active
$8.59
$-0.20(-2.28%)
Market Cap$449714306
P/E Ratio—
52W High$11.8
52W Low$4.76
Prothena Corporation plc (PRTA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PRTA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$0.52
Est. -$0.31 · +267.7%
Revenue
$0.05B
Est. $0.00B · +6215.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
PRTA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | -$0.39 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.31 | $0.52 | +267.7% | $0.05B | $0.00B | +6215.2% |
| ▲ Q1 FY2026 | Feb 19, 2026 | -$0.45 | -$0.44 | +2.2% | $0.00B | $0.00B | -98.4% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.60 | -$0.67 | -11.7% | $0.00B | $0.00B | +262.3% |
| ▼ Q3 FY2025 | Aug 4, 2025 | -$1.11 | -$1.86 | -67.6% | $0.00B | $0.01B | -33.4% |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.92 | -$1.12 | -21.7% | $0.00B | $0.02B | -81.6% |
| ▼ Q1 FY2025 | Feb 20, 2025 | -$1.02 | -$1.08 | -5.9% | $0.00B | $0.01B | -71.8% |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$1.18 | -$1.10 | +6.8% | $0.00B | $0.00B | -21.1% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
-$0.39
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
$0.52
EPS Est.
-$0.31
EPS Surpr.
+267.7%
Revenue
$0.05B
Q1 FY2026
Feb 19, 2026Beat
EPS Actual
-$0.44
EPS Est.
-$0.45
EPS Surpr.
+2.2%
Revenue
$0.00B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.67
EPS Est.
-$0.60
EPS Surpr.
-11.7%
Revenue
$0.00B
Q3 FY2025
Aug 4, 2025Miss
EPS Actual
-$1.86
EPS Est.
-$1.11
EPS Surpr.
-67.6%
Revenue
$0.00B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$1.12
EPS Est.
-$0.92
EPS Surpr.
-21.7%
Revenue
$0.00B
Q1 FY2025
Feb 20, 2025Miss
EPS Actual
-$1.08
EPS Est.
-$1.02
EPS Surpr.
-5.9%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$1.10
EPS Est.
-$1.18
EPS Surpr.
+6.8%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Q3 FY2027 | $-0.32 | $-0.32 | $-0.32 | 1 |
| Q2 FY2027 | $-0.34 | $-0.34 | $-0.34 | 1 |
| Q1 FY2027 | $-0.36 | $-0.36 | $-0.36 | 1 |
| Q4 FY2026 | $0.06 | $0.06 | $0.06 | 1 |
| Q3 FY2026 | $-0.24 | $-0.24 | $-0.23 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +267.7% | $11.18 | $10.52 | -5.90% |
| ▲ Q1 FY2026 | Feb 19, 2026 | +2.2% | $9.09 | $9.03 | -0.66% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -11.7% | $10.27 | $10.08 | -1.85% |
| ▼ Q3 FY2025 | Aug 4, 2025 | -67.6% | $6.81 | $6.94 | +1.91% |
| ▼ Q2 FY2025 | May 8, 2025 | -21.7% | $7.29 | $7.10 | -2.61% |
| ▼ Q1 FY2025 | Feb 20, 2025 | -5.9% | $14.98 | $15.25 | +1.80% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +6.8% | $18.08 | $17.36 | -3.98% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +216.2% | $19.26 | $19.68 | +2.18% |
Q2 FY2026-5.90%
Report Date
May 7, 2026
EPS Beat/Miss
+267.7%
Price Before
$11.18
Price After
$10.52
Q1 FY2026-0.66%
Report Date
Feb 19, 2026
EPS Beat/Miss
+2.2%
Price Before
$9.09
Price After
$9.03
Q4 FY2025-1.85%
Report Date
Nov 6, 2025
EPS Beat/Miss
-11.7%
Price Before
$10.27
Price After
$10.08
Q3 FY2025+1.91%
Report Date
Aug 4, 2025
EPS Beat/Miss
-67.6%
Price Before
$6.81
Price After
$6.94
Q2 FY2025-2.61%
Report Date
May 8, 2025
EPS Beat/Miss
-21.7%
Price Before
$7.29
Price After
$7.10
Q1 FY2025+1.80%
Report Date
Feb 20, 2025
EPS Beat/Miss
-5.9%
Price Before
$14.98
Price After
$15.25
Q4 FY2024-3.98%
Report Date
Nov 12, 2024
EPS Beat/Miss
+6.8%
Price Before
$18.08
Price After
$17.36
Q3 FY2024+2.18%
Report Date
Aug 8, 2024
EPS Beat/Miss
+216.2%
Price Before
$19.26
Price After
$19.68
Avg Beat Reaction-2.09%
Avg Miss Reaction-0.19%
Beat Rate4 / 8 quarters
Largest Move-5.90% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PRTA ends December
Prothena Corporation plc (PRTA) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.52 — beating the analyst consensus of $-0.31 by +267.7%. PRTA has beaten EPS estimates for 2 consecutive quarters. The next PRTA earnings date is expected around September 1, 2026.
Each quarter, investors track PRTA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PRTA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PRTA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PRTA earnings · 5 questionsProthena Corporation plc's next earnings report is expected around September 1, 2026. PRTA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PRTA historically reports after market close (AMC).
PRTA earnings datewhen is PRTA earningsPRTA next earnings datewhen does PRTA report earningsPRTA earnings calendar
▸ Source: FMP · Prothena Corporation plc SEC filings · US GAAP · Prothena Corporation plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026